Neostigmine is a reversible anticholinesterase agent indicated as a treatment for myasthenia gravis; and for use in the reversal of non-depolarizing muscle relaxants administered during surgery.

### General description

Neostigmine.

### INN

<table>
<thead>
<tr>
<th>INN</th>
<th>Neostigmine bromide</th>
</tr>
</thead>
</table>

### ATC codes

<table>
<thead>
<tr>
<th>ATC codes</th>
<th>N07AA01</th>
</tr>
</thead>
</table>

### Medicine type

Chemical agent

### EML status history

First added in 1977 (TRS 615) for **Anticholinesterase reversible**

Added in 1977 (TRS 615) for **Myasthenia gravis**

### Recommendations

**Muscle relaxants (peripherally-acting) and cholinesterase inhibitors**

Oral > Solid: 15 mg (neostigmine bromide)

Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)

### Indications

- Anticholinesterase reversible
- Myasthenia gravis